• Veena Madhuri Nadella
• Aravind Seema
• Navaneetha Nambigari

The regulation of cell growth and tissue development significantly influence apoptosis, also known as programmed cell death. Carcinogenesis is accelerated and chemotherapeutic drugs become resistant due to defects in apoptotic processes. So, increased erythropoietin (EPO) enzyme level is the cause of drug resistance in cancer. This calls for specialized, tailored techniques. The focused approach is based on the understanding of the disease-causing protein. Erythropoietin (EPO) overexpression causes angiogenesis in VEGF therapy resistance. The protein sequence (Uniprot ID P01588) is used in the current work for template identification, alignment, the building of 3D model using the SWISS model, and validation. A protein's 3D structure has 93.9% of amino acids in the favorable region, 6.1% in the generously allowed zone, and 0% in the disallowed region. Cast P located the active site residues LYS167, ARG158, THR71, LYS179, ASP192, GLY185, and ARG193.These amino acids have a part in both the signaling process and the way the EPO protein attaches to its natural substrate (EPOR). If this amino acids are blocked, the drug resistance can be inhibited. Researchers investigated the phytochemicals Dentatin (DEN), Nordentatin (NORD), and Quercetin (QUE) binding affinities for the EPO protein since these substances have shown anti-proliferative effects in a variety of cancer cell lines. These calculations showed that Nordentatin had a higher affinity for binding EPO than Quercetin and Dentatin (∆G values of 7.4 and 6.8 kcal/mol, respectively), but also suggest that all three compounds can block erythropoietin and overcome resistance.

Cancer, Drug resistance, Phytochemical and Insilico.

"Drug resistance in Cancer – An attempt to overcome by Homology Modeling, Validation and Docking of Erythropoietin protein. ", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.11, Issue 2, page no.a361-a369, February-2024, Available :http://www.jetir.org/papers/JETIR2402045.pdf

"Drug resistance in Cancer – An attempt to overcome by Homology Modeling, Validation and Docking of Erythropoietin protein. ", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.11, Issue 2, page no. ppa361-a369, February-2024, Available at : http://www.jetir.org/papers/JETIR2402045.pdf